Industrial - Machinery
Compare Stocks
5 / 10Stock Comparison
EMR vs AMAT vs LRCX vs HON vs GE
Revenue, margins, valuation, and 5-year total return — side by side.
Semiconductors
Semiconductors
Conglomerates
Aerospace & Defense
EMR vs AMAT vs LRCX vs HON vs GE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Industrial - Machinery | Semiconductors | Semiconductors | Conglomerates | Aerospace & Defense |
| Market Cap | $79.02B | $325.54B | $357.66B | $136.91B | $316.20B |
| Revenue (TTM) | $18.32B | $28.37B | $21.68B | $36.76B | $48.35B |
| Net Income (TTM) | $2.44B | $7.00B | $6.71B | $4.10B | $8.66B |
| Gross Margin | 52.7% | 48.7% | 50.0% | 36.9% | 34.8% |
| Operating Margin | 19.8% | 29.2% | 34.3% | 14.9% | 18.5% |
| Forward P/E | 21.7x | 39.3x | 51.8x | 20.2x | 39.3x |
| Total Debt | $13.76B | $6.55B | $4.76B | $34.58B | $20.49B |
| Cash & Equiv. | $1.54B | $7.24B | $6.39B | $12.49B | $12.39B |
EMR vs AMAT vs LRCX vs HON vs GE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Emerson Electric Co. (EMR) | 100 | 231.5 | +131.5% |
| Applied Materials, … (AMAT) | 100 | 774.9 | +674.9% |
| Lam Research Corpor… (LRCX) | 100 | 1074.4 | +974.4% |
| Honeywell Internati… (HON) | 100 | 146.1 | +46.1% |
| GE Aerospace (GE) | 100 | 908.4 | +808.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EMR vs AMAT vs LRCX vs HON vs GE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
EMR plays a supporting role in this comparison — it may shine differently against other peers.
AMAT is the clearest fit if your priority is sleep-well-at-night and valuation efficiency.
- Lower volatility, beta 2.14, Low D/E 32.1%, current ratio 2.61x
- PEG 2.29 vs HON's 11.03
LRCX carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 23.7%, EPS growth 43.1%, 3Y rev CAGR 2.3%
- 38.2% 10Y total return vs AMAT's 20.1%
- 23.7% revenue growth vs EMR's 3.0%
- 30.9% margin vs HON's 11.2%
HON is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- Dividend streak 15 yrs, beta 0.74, yield 2.1%
- Beta 0.74, yield 2.1%, current ratio 1.32x
- Lower P/E (20.2x vs 39.3x)
- Beta 0.74 vs LRCX's 2.54
Among these 5 stocks, GE doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 23.7% revenue growth vs EMR's 3.0% | |
| Value | Lower P/E (20.2x vs 39.3x) | |
| Quality / Margins | 30.9% margin vs HON's 11.2% | |
| Stability / Safety | Beta 0.74 vs LRCX's 2.54 | |
| Dividends | 2.1% yield, 15-year raise streak, vs EMR's 1.5% | |
| Momentum (1Y) | +282.9% vs HON's +2.8% | |
| Efficiency (ROA) | 31.4% ROA vs HON's 5.3%, ROIC 55.7% vs 12.6% |
EMR vs AMAT vs LRCX vs HON vs GE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
EMR vs AMAT vs LRCX vs HON vs GE — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
LRCX leads in 3 of 6 categories
HON leads 1 • EMR leads 0 • AMAT leads 0 • GE leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
LRCX leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
GE is the larger business by revenue, generating $48.4B annually — 2.6x EMR's $18.3B. LRCX is the more profitable business, keeping 30.9% of every revenue dollar as net income compared to HON's 11.2%. On growth, GE holds the edge at +24.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $18.3B | $28.4B | $21.7B | $36.8B | $48.4B |
| EBITDAEarnings before interest/tax | $4.7B | $8.4B | $7.8B | $6.5B | $9.9B |
| Net IncomeAfter-tax profit | $2.4B | $7.0B | $6.7B | $4.1B | $8.7B |
| Free Cash FlowCash after capex | $3.1B | $5.7B | $6.5B | $4.2B | $7.5B |
| Gross MarginGross profit ÷ Revenue | +52.7% | +48.7% | +50.0% | +36.9% | +34.8% |
| Operating MarginEBIT ÷ Revenue | +19.8% | +29.2% | +34.3% | +14.9% | +18.5% |
| Net MarginNet income ÷ Revenue | +13.3% | +24.7% | +30.9% | +11.2% | +17.9% |
| FCF MarginFCF ÷ Revenue | +17.0% | +20.1% | +29.8% | +11.4% | +15.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.9% | -3.5% | +23.8% | -6.9% | +24.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +28.2% | +13.9% | +40.8% | -41.9% | -1.1% |
Valuation Metrics
HON leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 29.4x trailing earnings, HON trades at a 57% valuation discount to LRCX's 69.0x P/E. Adjusting for growth (PEG ratio), AMAT offers better value at 2.76x vs HON's 15.99x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $79.0B | $325.5B | $357.7B | $136.9B | $316.2B |
| Enterprise ValueMkt cap + debt − cash | $91.2B | $324.9B | $356.0B | $159.0B | $324.3B |
| Trailing P/EPrice ÷ TTM EPS | 34.92x | 47.40x | 69.01x | 29.36x | 37.09x |
| Forward P/EPrice ÷ next-FY EPS est. | 21.70x | 39.27x | 51.78x | 20.24x | 39.27x |
| PEG RatioP/E ÷ EPS growth rate | 7.73x | 2.76x | 3.08x | 15.99x | 3.14x |
| EV / EBITDAEnterprise value multiple | 18.07x | 38.68x | 56.63x | 19.99x | 32.46x |
| Price / SalesMarket cap ÷ Revenue | 4.39x | 11.48x | 19.40x | 3.66x | 6.90x |
| Price / BookPrice ÷ Book value/share | 3.94x | 16.25x | 37.47x | 9.00x | 17.09x |
| Price / FCFMarket cap ÷ FCF | 29.63x | 57.13x | 66.06x | 25.39x | 43.53x |
Profitability & Efficiency
LRCX leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
LRCX delivers a 65.8% return on equity — every $100 of shareholder capital generates $66 in annual profit, vs $12 for EMR. AMAT carries lower financial leverage with a 0.32x debt-to-equity ratio, signaling a more conservative balance sheet compared to HON's 2.24x. On the Piotroski fundamental quality scale (0–9), LRCX scores 8/9 vs GE's 6/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +12.1% | +34.3% | +65.8% | +23.1% | +45.8% |
| ROA (TTM)Return on assets | +5.8% | +19.3% | +31.4% | +5.3% | +6.8% |
| ROICReturn on invested capital | +8.2% | +33.3% | +55.7% | +12.6% | +24.7% |
| ROCEReturn on capital employed | +10.0% | +30.6% | +40.4% | +12.6% | +9.6% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 8 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.68x | 0.32x | 0.48x | 2.24x | 1.08x |
| Net DebtTotal debt minus cash | $12.2B | -$686M | -$1.6B | $22.1B | $8.1B |
| Cash & Equiv.Liquid assets | $1.5B | $7.2B | $6.4B | $12.5B | $12.4B |
| Total DebtShort + long-term debt | $13.8B | $6.6B | $4.8B | $34.6B | $20.5B |
| Interest CoverageEBIT ÷ Interest expense | 6.46x | 35.46x | 58.92x | 3.92x | 11.69x |
Total Returns (Dividends Reinvested)
LRCX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GE five years ago would be worth $46,249 today (with dividends reinvested), compared to $10,326 for HON. Over the past 12 months, LRCX leads with a +282.9% total return vs HON's +2.8%. The 3-year compound annual growth rate (CAGR) favors LRCX at 76.4% vs HON's 5.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +4.3% | +52.9% | +54.9% | +10.9% | -5.5% |
| 1-Year ReturnPast 12 months | +30.4% | +164.7% | +282.9% | +2.8% | +44.9% |
| 3-Year ReturnCumulative with dividends | +75.9% | +258.7% | +448.8% | +16.2% | +280.0% |
| 5-Year ReturnCumulative with dividends | +59.5% | +213.8% | +360.5% | +3.3% | +362.5% |
| 10-Year ReturnCumulative with dividends | +206.6% | +2014.4% | +3815.1% | +135.1% | +121.0% |
| CAGR (3Y)Annualised 3-year return | +20.7% | +53.1% | +76.4% | +5.1% | +56.0% |
Risk & Volatility
Evenly matched — LRCX and HON each lead in 1 of 2 comparable metrics.
Risk & Volatility
HON is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than LRCX's 2.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LRCX currently trades 96.1% from its 52-week high vs EMR's 85.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.57x | 2.19x | 2.61x | 0.74x | 1.19x |
| 52-Week HighHighest price in past year | $165.15 | $432.81 | $298.00 | $248.18 | $348.48 |
| 52-Week LowLowest price in past year | $108.37 | $151.51 | $72.91 | $186.76 | $208.22 |
| % of 52W HighCurrent price vs 52-week peak | +85.4% | +94.8% | +96.1% | +87.1% | +86.8% |
| RSI (14)Momentum oscillator 0–100 | 61.3 | 66.3 | 69.9 | 45.1 | 56.4 |
| Avg Volume (50D)Average daily shares traded | 2.8M | 6.0M | 9.7M | 3.7M | 5.7M |
Analyst Outlook
Evenly matched — EMR and HON each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: EMR as "Buy", AMAT as "Buy", LRCX as "Buy", HON as "Buy", GE as "Buy". Consensus price targets imply 27.6% upside for GE (target: $386) vs 1.7% for LRCX (target: $291). For income investors, HON offers the higher dividend yield at 2.14% vs LRCX's 0.31%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $161.31 | $437.10 | $291.17 | $243.83 | $386.20 |
| # AnalystsCovering analysts | 41 | 53 | 50 | 28 | 34 |
| Dividend YieldAnnual dividend ÷ price | +1.5% | +0.4% | +0.3% | +2.1% | +0.4% |
| Dividend StreakConsecutive years of raises | 37 | 8 | 11 | 15 | 2 |
| Dividend / ShareAnnual DPS | $2.10 | $1.71 | $0.89 | $4.63 | $1.36 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.6% | +1.5% | +1.0% | +2.8% | +2.4% |
LRCX leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HON leads in 1 (Valuation Metrics). 2 tied.
EMR vs AMAT vs LRCX vs HON vs GE: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is EMR or AMAT or LRCX or HON or GE a better buy right now?
For growth investors, Lam Research Corporation (LRCX) is the stronger pick with 23.
7% revenue growth year-over-year, versus 3. 0% for Emerson Electric Co. (EMR). Honeywell International Inc. (HON) offers the better valuation at 29. 4x trailing P/E (20. 2x forward), making it the more compelling value choice. Analysts rate Emerson Electric Co. (EMR) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EMR or AMAT or LRCX or HON or GE?
On trailing P/E, Honeywell International Inc.
(HON) is the cheapest at 29. 4x versus Lam Research Corporation at 69. 0x. On forward P/E, Honeywell International Inc. is actually cheaper at 20. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Applied Materials, Inc. wins at 2. 29x versus Honeywell International Inc. 's 11. 03x.
03Which is the better long-term investment — EMR or AMAT or LRCX or HON or GE?
Over the past 5 years, GE Aerospace (GE) delivered a total return of +362.
5%, compared to +3. 3% for Honeywell International Inc. (HON). Over 10 years, the gap is even starker: LRCX returned +39. 2% versus GE's +117. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EMR or AMAT or LRCX or HON or GE?
By beta (market sensitivity over 5 years), Honeywell International Inc.
(HON) is the lower-risk stock at 0. 74β versus Lam Research Corporation's 2. 61β — meaning LRCX is approximately 252% more volatile than HON relative to the S&P 500. On balance sheet safety, Applied Materials, Inc. (AMAT) carries a lower debt/equity ratio of 32% versus 2% for Honeywell International Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — EMR or AMAT or LRCX or HON or GE?
By revenue growth (latest reported year), Lam Research Corporation (LRCX) is pulling ahead at 23.
7% versus 3. 0% for Emerson Electric Co. (EMR). On earnings-per-share growth, the picture is similar: Lam Research Corporation grew EPS 43. 1% year-over-year, compared to -15. 5% for Honeywell International Inc.. Over a 3-year CAGR, GE leads at 16. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EMR or AMAT or LRCX or HON or GE?
Lam Research Corporation (LRCX) is the more profitable company, earning 29.
1% net margin versus 12. 6% for Honeywell International Inc. — meaning it keeps 29. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LRCX leads at 32. 0% versus 17. 5% for HON. At the gross margin level — before operating expenses — EMR leads at 52. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EMR or AMAT or LRCX or HON or GE more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Applied Materials, Inc. (AMAT) is the more undervalued stock at a PEG of 2. 29x versus Honeywell International Inc. 's 11. 03x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Honeywell International Inc. (HON) trades at 20. 2x forward P/E versus 51. 8x for Lam Research Corporation — 31. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GE: 27. 6% to $386. 20.
08Which pays a better dividend — EMR or AMAT or LRCX or HON or GE?
All stocks in this comparison pay dividends.
Honeywell International Inc. (HON) offers the highest yield at 2. 1%, versus 0. 3% for Lam Research Corporation (LRCX).
09Is EMR or AMAT or LRCX or HON or GE better for a retirement portfolio?
For long-horizon retirement investors, Honeywell International Inc.
(HON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 74), 2. 1% yield, +132. 4% 10Y return). Applied Materials, Inc. (AMAT) carries a higher beta of 2. 19 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HON: +132. 4%, AMAT: +21. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EMR and AMAT and LRCX and HON and GE?
These companies operate in different sectors (EMR (Industrials) and AMAT (Technology) and LRCX (Technology) and HON (Industrials) and GE (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: EMR is a mid-cap quality compounder stock; AMAT is a large-cap quality compounder stock; LRCX is a large-cap high-growth stock; HON is a mid-cap quality compounder stock; GE is a large-cap high-growth stock. EMR, HON pay a dividend while AMAT, LRCX, GE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.